Form 4: MAIA Biotechnology Insider Stock Option Grant

Sergei Gryaznov, Chief Scientific Officer of MAIA Biotechnology, Inc., was granted 400,000 stock options with an exercise price of $1.28.

Summary

• Sergei Gryaznov, Chief Scientific Officer at MAIA Biotechnology, Inc., received a grant of 400,000 stock options on April 10, 2026.
• These options have an exercise price of $1.28 per share.
• The options were granted under the company's 2021 Equity Incentive Plan.
• Vesting occurs over a four-year schedule: 25% on the first anniversary of the grant date, followed by monthly vesting for the subsequent 36 months.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports on a standard executive compensation event (stock option grant) without providing new financial performance data or strategic updates.

Positives

• Grant of stock options to a key executive (Chief Scientific Officer) can incentivize performance and align executive interests with shareholders.
• The exercise price of $1.28 suggests a potential for future stock price appreciation if the company's value increases.
• The 4-year vesting schedule promotes long-term commitment from the executive.

Negatives

• The filing does not provide information on the company's current financial performance or valuation, making it difficult to assess the immediate value of the options.
• The grant is a forward-looking incentive, and its actual benefit is contingent on future stock performance.

Risks

• The value of the stock options is directly tied to the future performance of MAIA Biotechnology's stock price, which is subject to market volatility and company-specific risks.
• If the company's stock price does not exceed the exercise price of $1.28, the options will not be profitable.
• The vesting schedule means the executive does not immediately own the underlying shares, and any early departure could impact the realization of these options.

Future Outlook

The grant of stock options with a future vesting schedule indicates management's expectation of future stock price appreciation, though no specific financial projections are provided in this filing.

Management Comments

• The stock options were granted pursuant to MAIA Biotechnology, Inc's 2021 Equity Incentive Plan.
• The options vest on a 4-year schedule, with 25% on the first anniversary and the remainder vesting monthly thereafter.

Industry Context

StockSavvy.ai notes that the granting of stock options to key scientific officers is a common practice in the biotechnology sector to attract and retain talent, especially in early-stage companies where significant future growth is anticipated.

Stakeholder Impact

• Shareholders: The grant of options dilutes existing share ownership slightly, but it also serves as an incentive for executive performance, which could positively impact shareholder value if successful.
• Employees: May be seen as a positive sign of executive commitment and potential future growth, though direct impact is limited.
• Management: Reinforces the executive's role and provides a financial stake in the company's success.

Next Steps

• The options will vest according to the specified schedule over four years.
• The executive may exercise the vested options if the stock price is above the $1.28 exercise price.

Key Dates

Keywords

MAIA Biotechnology, Form 4, Stock Options, Insider Trading, Executive Compensation, Securities Exchange Act, Equity Incentive Plan, Sergei Gryaznov